JWH-369

JWH-369

0JWH-369 is a synthetic cannabinoid from the naphthoylindole family. It acts as a potent and selective agonist for the CB2 receptor, with a binding affinity of 13.8nM at CB2 and 383nM at CB1, giving it around 28x selectivity for CB2.

Chemistry

JWH-369 is part of the JWH series of synthetic cannabinoids, named after the initials of the chemist who first synthesized them, John W. Huffman. The JWH series includes a range of compounds that vary in their chemical structures and pharmacological properties. JWH-369 is a naphthoylindole, meaning it is composed of a naphthoyl group attached to an indole core.

Pharmacology

JWH-369 acts as a potent and selective agonist for the CB2 receptor, a type of cannabinoid receptor found primarily in the immune system. It has a binding affinity of 13.8nM at CB2, making it a highly potent ligand for this receptor. In contrast, it has a much lower binding affinity of 383nM at the CB1 receptor, which is the other main type of cannabinoid receptor and is found primarily in the brain. This gives JWH-369 a selectivity ratio of around 28x for the CB2 receptor over the CB1 receptor.

Effects

The effects of JWH-369 are not well-studied, but based on its pharmacological profile, it is likely to produce effects similar to those of other CB2-selective agonists. These may include anti-inflammatory and immunomodulatory effects, as the CB2 receptor is known to play a role in immune function. However, as JWH-369 also has some activity at the CB1 receptor, it may also produce some psychoactive effects, although these are likely to be less pronounced than those of CB1-selective agonists.

Legal Status

The legal status of JWH-369 varies by country and region. In many places, it is considered a controlled substance due to its structural similarity to other synthetic cannabinoids, which are often subject to legal restrictions.

See Also

• JWH-018
• JWH-073
• JWH-200
• Cannabinoid receptor
• Synthetic cannabinoids